Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.

Çınar, OE; Sayınalp, BAŞAK; Aladağ, Karakulak; Avşar, Karataş; Velet, M; İnkaya, AHMET; Ersoy, Ortaç; Öcal, S; Aksu, S; Haznedaroğlu, İC; Sayınalp, NİLGÜN; Özcebe, Oİ

doi:10.1016/j.transci.2020.102821

Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.

Çınar O., Sayınalp B., Aladağ K., Avşar K., Velet M., İnkaya A. Ç., ...Daha Fazla

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, cilt.59, ss.102821, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 59
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.transci.2020.102821
Dergi Adı: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
Sayfa Sayıları: ss.102821
Anahtar Kelimeler: COVID-19, Convalescent, Plasmapheresis, Myelodysplastic, Tuberculosis
Hacettepe Üniversitesi Adresli: Evet

Özet

During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.